DE3483504D1 - Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung. - Google Patents

Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung.

Info

Publication number
DE3483504D1
DE3483504D1 DE8484305911T DE3483504T DE3483504D1 DE 3483504 D1 DE3483504 D1 DE 3483504D1 DE 8484305911 T DE8484305911 T DE 8484305911T DE 3483504 T DE3483504 T DE 3483504T DE 3483504 D1 DE3483504 D1 DE 3483504D1
Authority
DE
Germany
Prior art keywords
amosulalol hydrochloride
long
lasting effect
hydrochloride formulations
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8484305911T
Other languages
English (en)
Inventor
Takashi Sonobe
Hiroshi Sugiura
Tomoh Itoh
Masayoshi Aruga
Hiroitsu Kawata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3483504D1 publication Critical patent/DE3483504D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8484305911T 1983-08-31 1984-08-29 Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung. Expired - Fee Related DE3483504D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58160086A JPS6051106A (ja) 1983-08-31 1983-08-31 塩酸アモスラロ−ル持続性製剤

Publications (1)

Publication Number Publication Date
DE3483504D1 true DE3483504D1 (de) 1990-12-06

Family

ID=15707557

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484305911T Expired - Fee Related DE3483504D1 (de) 1983-08-31 1984-08-29 Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung.

Country Status (7)

Country Link
US (2) US4724148A (de)
EP (1) EP0136103B1 (de)
JP (1) JPS6051106A (de)
KR (1) KR910002670B1 (de)
AT (1) ATE57833T1 (de)
DE (1) DE3483504D1 (de)
ES (1) ES535545A0 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
DE69020758T2 (de) * 1989-03-10 1995-12-07 Yamanouchi Pharma Co Ltd Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen.
US5258186A (en) * 1989-03-10 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Drug release controlling coating material for long acting formulations
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
US5523289A (en) * 1991-04-15 1996-06-04 Abbott Laboratories Pharmaceutical composition
NZ242806A (en) * 1991-05-20 1994-01-26 Marion Laboratories Inc Multi-layered acid-containing coated drug beads.
FR2737494B1 (fr) * 1995-08-04 1997-08-29 Synthelabo Derives de benzenesulfonamide, leur preparation et leur application en therapeutique
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
WO1999057131A1 (en) * 1998-05-06 1999-11-11 Duke University Method of treating bladder and lower urinary tract syndromes
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
AU1169601A (en) * 1999-11-16 2001-05-30 Ranbaxy Laboratories Limited Taste masked oral compositions
JP4494712B2 (ja) * 2002-11-12 2010-06-30 大日本住友製薬株式会社 マルチプルユニット型徐放性製剤
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
US9072670B2 (en) 2007-10-19 2015-07-07 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
DE102011012517A1 (de) * 2011-02-25 2012-08-30 Renolit Ag Verfahren zum Schutz von Oberflächen vor Bewuchs
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT270071B (de) * 1966-08-12 1969-04-10 Roehm & Haas Gmbh Dragierlack für Arzneiformen
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
JPS535728B2 (de) * 1974-01-12 1978-03-01
CA1097220A (en) * 1975-10-10 1981-03-10 Aaron L. Weiss Controlled release tablet
CA1147342A (en) * 1977-10-12 1983-05-31 Kazuo Imai Process of producing novel phenylethanolamine derivatives
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4289750A (en) * 1978-10-16 1981-09-15 Kopp Klaus F Therapy of conditions which may be associated with altered renal function and dosage forms therefor
JPS606330B2 (ja) * 1978-11-30 1985-02-18 山之内製薬株式会社 α・β両遮断剤
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤

Also Published As

Publication number Publication date
KR850001693A (ko) 1985-04-01
ES8602406A1 (es) 1985-12-01
KR910002670B1 (ko) 1991-05-03
EP0136103A3 (en) 1986-10-22
EP0136103A2 (de) 1985-04-03
ATE57833T1 (de) 1990-11-15
ES535545A0 (es) 1985-12-01
US4724148A (en) 1988-02-09
JPS6051106A (ja) 1985-03-22
US4765988A (en) 1988-08-23
JPH0443049B2 (de) 1992-07-15
EP0136103B1 (de) 1990-10-31

Similar Documents

Publication Publication Date Title
DE3483504D1 (de) Amosulalolhydrochlorid-formulierungen mit lang anhaltender wirkung.
DK315884D0 (da) Fremgangsmaade til percutan anvendelse af fysiologisk aktive midler under anvendelse af et alkohol-hjaelpestof og et oploesningsmiddel
DE3880047D1 (de) Zusammensetzung eines zusatzes.
IT8519352A0 (it) Applicazione di un manicotto elastico su un corpo allungato
IT1131750B (it) Formulazioni stabili di n-(3,4-diclorofenil)-n'metossi-n'-metilurea (linorun) e 2,6-dinitor-n,n-dipropil-4-trifluoro metilanilina (trifluralin) in emulsione
KR920701213A (ko) 메틸렌디포스폰산 화합물 및 그것을 유효성분으로 하는 항염증제
FR2482860B1 (fr) Composition et preparation d'un agent antimicrobien
IT1174756B (it) Composizioni antisolari contenenti almeno un composto di ammide viniloga e relativo impiego
TR20232A (tr) Cis-9-trikosen ve metomil'den olusan ensektisit bilesim
FI791565A (fi) Farmaceutiska sammansaettningar innehaollande prostaglandinfoereningar
SE8002642L (sv) Analgetiska och myotonolytiska preparat
IT1157914B (it) Formulazioni insetticide a base di piretroidi e esteritioffosforici
NO165372C (no) Anvendelse av aminoalkanfosfonsyrer og derivater derav som fungicide midler.
NZ192771A (en) N-(4-alkenylthio-phenyl)-n'-benzoylureas and insecticidal compositions
IL62663A (en) Synergistic fungicidal compositions comprising n-(2,6-dimethylphenyl)-n-(1-methoxycarbonylethyl)-phenylacetamide and another fungicide
ES2053686T3 (es) Nuevos di(met)acrilatos, procedimiento para su fabricacion y su empleo.
IT1152114B (it) Procedimento di alogenazione di n-(0,0'-dialchilfenil) alaninati e omologhi
KR910000645A (ko) 개선된 경련치료제
ZA836173B (en) Soil repellents derived from fluorinated acrylates and aromatic amines
ATE6401T1 (de) Schaedlingsbekaempfungsmittel.
DK155831C (da) N-phenyl-n'-benzoyl-urinstofderivater og deres anvendelse som skadedyrsbekaempelsesmidler
IT1184671B (it) Composizione erbicida e procedimento per la preparazione del suo ingrediente attivo
IT1135788B (it) Perfezionamento alle apparecchiature spandi-erba ed equivalenti applicazioni agrarie,e relative apparecchiature perfezionate
AT380191B (de) Elastische huelse fuer den spreizdorn eines haspels
ES477659A1 (es) Procedimiento para preparar n-(cloroalcanoil)-n'-trifluorme-tilfenilureas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee